BioVie BIVI Stock
BioVie Price Chart
BioVie BIVI Financial and Trading Overview
| BioVie stock price | 2.16 USD |
| Previous Close | 2.19 USD |
| Open | 2.2 USD |
| Bid | 1.62 USD x 200 |
| Ask | 2.72 USD x 200 |
| Day's Range | 2.11 - 2.25 USD |
| 52 Week Range | 0.82 - 3.79 USD |
| Volume | 474.47K USD |
| Avg. Volume | 4.58M USD |
| Market Cap | 18.25M USD |
| Beta (5Y Monthly) | 0.667 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.05 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.26 USD |
BIVI Valuation Measures
| Enterprise Value | 7.82M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.7894738 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.5859032 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.348 |
Trading Information
BioVie Stock Price History
| Beta (5Y Monthly) | 0.667 |
| 52-Week Change | 44.07% |
| S&P500 52-Week Change | 19.66% |
| 52 Week High | 3.79 USD |
| 52 Week Low | 0.82 USD |
| 50-Day Moving Average | 1.7 USD |
| 200-Day Moving Average | 1.48 USD |
BIVI Share Statistics
| Avg. Volume (3 month) | 4.58M USD |
| Avg. Daily Volume (10-Days) | 13.16M USD |
| Shares Outstanding | 8.45M |
| Float | 7.5M |
| Short Ratio | 0.2 |
| % Held by Insiders | 0.29% |
| % Held by Institutions | 19.77% |
| Shares Short | 1.25M |
| Short % of Float | 14.91% |
| Short % of Shares Outstanding | 14.84% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2026 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | June 30, 2027 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -79.063% |
| Return on Equity (ttm) | -150.75% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -22473392 USD |
| Net Income Avi to Common (ttm) | -22116408 USD |
| Diluted EPS (ttm) | -3.05 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.98M USD |
| Total Cash Per Share (mrq) | 1.19 USD |
| Total Debt (mrq) | 275.43K USD |
| Total Debt/Equity (mrq) | 2.68 USD |
| Current Ratio (mrq) | 3.594 |
| Book Value Per Share (mrq) | 1.362 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -19024806 USD |
| Levered Free Cash Flow (ttm) | -11123067 USD |
Profile of BioVie
| Country | United States |
| State | NV |
| City | Carson City |
| Address | 680 W. Nye Lane |
| ZIP | 89703 |
| Phone | 775 888 3162 |
| Website | https://bioviepharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 13 |
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Q&A For BioVie Stock
What is a current BIVI stock price?
BioVie BIVI stock price today per share is 2.16 USD.
How to purchase BioVie stock?
You can buy BIVI shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioVie?
The stock symbol or ticker of BioVie is BIVI.
Which industry does the BioVie company belong to?
The BioVie industry is Biotechnology.
How many shares does BioVie have in circulation?
The max supply of BioVie shares is 8.45M.
What is BioVie Price to Earnings Ratio (PE Ratio)?
BioVie PE Ratio is now.
What was BioVie earnings per share over the trailing 12 months (TTM)?
BioVie EPS is -3.05 USD over the trailing 12 months.
Which sector does the BioVie company belong to?
The BioVie sector is Healthcare.
BioVie BIVI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26402.42 USD — |
-0.52
|
7.53B USD — | 26359.27 USD — | 26700.68 USD — | — - | 7.53B USD — |
|
US Tech Health Care
IXHC
US
|
1339.84 USD — |
-2.05
|
— — | 1338.76 USD — | 1360.4 USD — | — - | — — |
- {{ link.label }} {{link}}
